Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC1 | Q13547 | 14/20 | 0.71 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.71 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.71 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.71 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.71 |
| ▸ | HDAC10 | Q969S8 | 2/20 | 0.71 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.71 |
| ▸ | RARB | P10826 | 1/20 | 0.54 |
| ▸ | KDM1A | O60341 | 2/20 | 0.52 |
| ▸ | MAOA | P21397 | 2/20 | 0.52 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17478531 | 1.00 | HDAC1 (0.71) | HDAC1HDAC6HDAC2HDAC3HDAC5 | |
| SCHEMBL17478501 | 1.00 | HDAC1 (0.71) | HDAC1HDAC6HDAC2HDAC3HDAC5 | |
| SCHEMBL19666050 | 1.00 | HDAC1 (0.71) | HDAC1HDAC6HDAC2HDAC3HDAC5 | |
| SCHEMBL19682890 | 0.90 | HDAC1 (0.57) | HDAC1HDAC6HDAC2HDAC3HDAC5 | |
| SCHEMBL17478445 | 0.90 | HDAC6 (0.73) | HDAC1HDAC6HDAC2HDAC3HDAC5 | |
| SCHEMBL17478446 | 0.90 | HDAC6 (0.73) | HDAC1HDAC6HDAC2HDAC3HDAC5 | |
| SCHEMBL18088443 | 0.89 | HDAC1 (0.64) | HDAC1HDAC6HDAC2HDAC3HDAC5 | |
| SCHEMBL17483933 | 0.89 | HDAC1 (0.64) | HDAC1HDAC6HDAC2HDAC3HDAC5 | |
| SCHEMBL17483902 | 0.87 | HDAC1 (0.67) | HDAC1HDAC6HDAC2HDAC3HDAC5 | |
| SCHEMBL17483897 | 0.87 | HDAC3 (0.67) | HDAC1HDAC6HDAC2HDAC3HDAC5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121574593-A | Primer coating ink for metal surface and preparation method and application thereof | 中钞油墨有限公司 | 2026-02-27 | — | — | CN | claimed |
| CN-122037657-A | Ink composition and application thereof | 昆山百柔新材料技术有限公司 | 2026-05-15 | — | — | CN | disclosed |
| EP-4720766-A1 | NARROW FIELD OF VIEW ANGULAR LIGHT CONTROL FILM | 3M Innovative Properties Company (US) | 2026-04-08 | — | — | EP | disclosed |
| CN-121574593-A | Primer coating ink for metal surface and preparation method and application thereof | 中钞油墨有限公司 | 2026-02-27 | — | — | CN | disclosed |
| US-20260022277-A1 | CURABLE COMPOSITIONS | ARKEMA FRANCE (FR) | 2026-01-22 | — | — | US | disclosed |
| US-12491270-B2 | Imaging histone deacetylases with a radiotracer using positron emission tomography | THE GENERAL HOSPITAL CORPORATION (US) | 2025-12-09 | — | — | US | disclosed |
| WO-2025215194-A1 | ENHANCED REMOVABILITY OF NAIL COATINGS USING ACIDIC COPOLYMERS FOR TRIGGERED REMOVAL WITH AQUEOUS BASED REMOVER | ARKEMA FRANCE (FR) | 2025-10-16 | — | — | WO | disclosed |
| US-12418013-B2 | Method of solvent-free manufacturing of composite electrodes incorporating radiation curable binders | UT-BATTELLE, LLC (US) | 2025-09-16 | — | — | US | disclosed |
| EP-3955900-B1 | POLYMERIC CAPSULES | PROCTER & GAMBLE (US) | 2025-07-23 | — | — | EP | disclosed |
| EP-3701299-B1 | METHOD OF MAKING A RETROREFLECTIVE ARTICLE COMPRISING LOCALLY-LAMINATED REFLECTIVE LAYERS | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2025-05-28 | — | — | EP | disclosed |
| US-11289689-B2 | Method of solvent-free manufacturing of composite electrodes incorporating radiation curable binders | UTBATTELE, LLC (US) | 2022-03-29 | — | — | US | disclosed |
| US-11278857-B2 | Polymeric capsules | THE PROCTER & GAMBLE COMPANY (US) | 2022-03-22 | — | — | US | disclosed |
| CN-110475827-B | Radiation curable ink compositions, printed articles, and methods of using the same | 花王株式会社 | 2022-02-15 | — | — | CN | disclosed |
| CN-114040773-A | Lysin and derivatives thereof having bactericidal activity against pseudomonas aeruginosa in the presence of human serum | 康特拉费克特公司 | 2022-02-11 | — | — | CN | disclosed |
| US-20210030899-A1 | IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY | THE GENERAL HOSPITAL CORPORATION | 2021-02-04 | — | — | US | disclosed |
| US-10842891-B2 | Imaging histone deacetylases with a radiotracer using positron emission tomography | THE GENERAL HOSPITAL CORPORATION (US) | 2020-11-24 | — | — | US | disclosed |
| US-20190240357-A1 | IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY | THE GENERAL HOSPITAL CORPORATION | 2019-08-08 | — | — | US | disclosed |
| US-10188756-B2 | Imaging histone deacetylases with a radiotracer using positron emission tomography | THE GENERAL HOSPITAL CORPORATION (US) | 2019-01-29 | — | — | US | disclosed |
| US-20170349540-A1 | HISTONE DEACETYLASE INHIBITORS | THE GENERAL HOSPITAL CORPORATION | 2017-12-07 | — | — | US | disclosed |
| US-20170349540-A1 | HISTONE DEACETYLASE INHIBITORS | THE GENERAL HOSPITAL CORPORATION | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190240357-A1 | IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885HDAC6 13/4885HDAC2 4/4885 |
| US-10188756-B2 | Imaging histone deacetylases with a radiotracer using positron emission tomography | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885HDAC6 13/4885HDAC2 4/4885 |
| US-20210030899-A1 | IMAGING HISTONE DEACETYLASES WITH A RADIOTRACER USING POSITRON EMISSION TOMOGRAPHY | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885HDAC6 13/4885HDAC2 4/4885 |
| US-12491270-B2 | Imaging histone deacetylases with a radiotracer using positron emission tomography | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885HDAC6 13/4885HDAC2 4/4885 |
| US-20170349540-A1 | HISTONE DEACETYLASE INHIBITORS | HDAC1, HDAC11, HDAC5 | HDAC1 1/4885HDAC6 10/4885HDAC2 4/4885 |
| US-20260022277-A1 | CURABLE COMPOSITIONS | MTDH, MYO1G, TPM3 | HDAC1 3039/4885HDAC6 1374/4885HDAC2 4078/4885 |
| US-10842891-B2 | Imaging histone deacetylases with a radiotracer using positron emission tomography | HDAC1, HDAC11, HDAC3 | HDAC1 1/4885HDAC6 13/4885HDAC2 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.